Date:
November 1, 2021
Issue #:
1636
Summary:
The FDA has approved an expansion of the
peripheral artery disease (PAD) indication for the
oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently
undergone a lower extremity revascularization
procedure for symptomatic PAD (see Table 1).
Rivaroxaban is the first direct oral anticoagulant
(DOAC) to be approved for use in patients with PAD.
peripheral artery disease (PAD) indication for the
oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently
undergone a lower extremity revascularization
procedure for symptomatic PAD (see Table 1).
Rivaroxaban is the first direct oral anticoagulant
(DOAC) to be approved for use in patients with PAD.
